2023 World Conference on Lung Cancer (Posters)-EP07.05. The Efficacy of Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemotherapy in Resectable NSCLC, a Comparison Research from Real World

EP07.05. The Efficacy of Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemotherapy in Resectable NSCLC, a Comparison Research from Real World - PDF(Abstract)

Back to course

Pdf Summary

This research study compared the efficacy of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The study aimed to determine the differences in efficacy between the two approaches and identify factors related to prognosis. <br /><br />The study included 57 patients who received neoadjuvant chemoimmunotherapy and 46 patients who received neoadjuvant chemotherapy. The results showed that neoadjuvant immunotherapy plus chemotherapy had higher objective response rates (75%), major pathological response rates (63%), and pathological complete response rates (37%) compared to neoadjuvant chemotherapy alone. Additionally, patients in the neoadjuvant chemoimmunotherapy group had more favorable recurrence-free survival and overall survival rates.<br /><br />The study also found a strong correlation between major pathological response status and recurrence-free survival in patients who received neoadjuvant chemoimmunotherapy. This suggests that achieving a major pathological response could be a significant predictor of better outcomes in patients treated with neoadjuvant immunotherapy plus chemotherapy.<br /><br />Based on these findings, the researchers recommend neoadjuvant immunotherapy combined with chemotherapy as a superior treatment option for resectable NSCLC. They also emphasize the importance of achieving a major pathological response for improved recurrence-free survival in patients undergoing neoadjuvant chemoimmunotherapy.<br /><br />In summary, this study demonstrates the efficacy of neoadjuvant chemoimmunotherapy compared to neoadjuvant chemotherapy in patients with resectable NSCLC. It provides evidence that neoadjuvant immunotherapy plus chemotherapy produces higher response rates and better prognosis.

Asset Subtitle

Xinying Xue

Meta Tag

Speaker Xinying Xue

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

neoadjuvant chemoimmunotherapy

neoadjuvant chemotherapy

non-small cell lung cancer

efficacy

objective response rates

major pathological response rates

pathological complete response rates

recurrence-free survival

overall survival rates

major pathological response status